- Open Access
Changes in ovarian function in premenopausal women with breast cancer undergoing adjuvant TC (docetaxel and cyclophosphamide) chemotherapy during a brief period of amenorrhea around the last chemotherapy cycle
© Yoshimura and Furuya; licensee Springer. 2014
- Received: 1 July 2014
- Accepted: 1 July 2014
- Published: 10 July 2014
Docetaxel, a chemotherapeutic agent, induces high rates of transient chemotherapy-induced amenorrhea (CIA) when used as adjuvant chemotherapy for premenopausal women with breast cancer. Clinical laboratory data to assess the hormonal environment implicated in inducing transient CIA was assessed.
An observational study was conducted in 35 premenopausal women with hormone-responsive breast cancer who were receiving adjuvant docetaxel/cyclophosphamide (TC) chemotherapy. Serum estradiol and follicular stimulating hormone (FSH) levels were measured at one (n = 6) or two (n = 29) time point(s) around the completion of chemotherapy.
As early as week 6 after the start of chemotherapy, just before the third TC cycle, serum estradiol levels were invariably suppressed (median of 5.5 pg/ml, n = 15, range <5–18.7 pg/ml) and FSH levels increased (median of 63.9 mIU/ml, range 24.5–127.4 mIU/ml), indicative of ovarian suppression to the menopausal levels. Subsequently, at 9 and 12 weeks, serum estradiol levels were suppressed to a median of 6.6 pg/ml (n = 49, range <5–17.3 pg/ml), while FSH levels were high (median of 66.8 mIU/ml, range 29.2–134.5 mIU/ml). There was a significant Spearman’s correlation (ρ = 0.95, n = 29, p < 0.01) of high serum FSH levels (24.5–134.5 mIU/ml) between two time points of repeated measurements in 29 patients. TC chemotherapy induced rapid ovarian suppression with the formation of a high and stable plateau in serum FSH levels from week 6 to week 12.
Recovery from transient CIA post-therapy may be partially attributed to high, stable FSH levels that occurred as early as after completion of the second TC chemotherapy cycle.
- Adjuvant treatment
- Early breast cancer
Breast cancer is a heterogeneous disease for which optimal treatment must be tailored to a specific breast cancer type (Goldhirsch et al. 2007; Nguyen et al. 2008). Age and menstrual status are taken into consideration when treatment is being planned for patients with early breast cancer. Docetaxel-containing chemotherapy, TC (docetaxel/cyclophosphamide), has been reported to be associated with a better overall survival benefit compared with second generation chemotherapy, AC (doxorubicin/cyclophosphamide), and has become one of the standard adjuvant chemotherapy regimens for the treatment of early breast cancer (Jones et al. 2006; Jones et al. 2009).
Chemotherapy-induced amenorrhea (CIA) varies in type and onset. Amenorrhea was shown to be transient, lasting for 3 (Parulekar et al. 2005; Yoo et al. 2013) or 6 months (Swain & Land 2009; Park et al. 2012; Swain et al. 2010a; Swain et al. 2010b), or persistent. Onset of amenorrhea occurred anywhere from soon after chemotherapy completion to up to 24 months of follow-up. At the 12-month assessment, after either first or second-generation chemotherapy, 41% of patients who were not amenorrheic at the 6-month assessment had CIA (Parulekar et al. 2005). Docetaxel-containing chemotherapy caused amenorrhea at a relatively high rate soon after chemotherapy completion, but at the later periods, 12 and 36 months, the rate of CIA was relatively lower (Berliere et al. 2008; Han et al. 2009). Most (92%) premenopausal women treated with AC followed by docetaxel in the NSABP B-30 clinical trial were reported to become amenorrheic for a short period (<3 months), while 45.3% of women <40 years of age resumed menses at the 2 year assessment (Swain & Land 2009). Anderson et al. demonstrated that serum estradiol concentrations decreased at six months only in women who had completed a six-month course of a docetaxel-containing regimen (anthracycline-based chemotherapy followed by docetaxel) (Anderson et al. 2006). It may be possible to determine if there was a brief period of amenorrhea, which the patient might not have recorded even if there was no vaginal bleeding at the time of TC chemotherapy completion, by monitoring ovarian function.
CIA has been associated with clinically important effects on symptoms and quality of life (Knobf 2006). We sought to describe our own experience in this observational study by monitoring serum estradiol and follicle-stimulating hormone (FSH) levels to provide information on changes in serum estradiol levels to deal with the predictable symptoms caused by such hormonal changes, and to gain insight into the underlying hormonal changes due to current CIA.
This study was limited by the small number of patients; however, to the best of our knowledge, this is the first report to show that TC chemotherapy in premenopausal women with hormone-responsive breast cancer induced ovarian suppression at the time of chemotherapy completion, as assessed using clinical laboratory measurements of serum estradiol and FSH.
Between May 2009 and March 2014, 35 consecutive premenopausal patients with ER-positive early breast cancer at medium risk who had completed adjuvant TC chemotherapy treatment after surgery were analyzed. Premenopausal status of these patients was defined in this cohort as having regular menses before surgery.
Patient baseline characteristics
TC group (n=35)
Our original study aim was to monitor changes in serum FSH and estradiol levels three weeks after completion of TC chemotherapy to gather information on baseline levels of the ovarian function, to be compared with levels at the resumption of menses, and all patients gave their consent on this basis. We expanded our study plan to include two time points from earlier cycles of chemotherapy to help pinpoint when estradiol suppression had occurred, because an unexpected stable decline of serum estradiol levels was observed in all patients. Consent to take these additional serum samples was obtained from 29 patients. Fasting morning samples were collected at weeks 6 and 9, just before the start of the third and fourth cycles of chemotherapy, concomitant with regular white blood cell count checks before chemotherapy. Blood samples were also collected from patients not fasting at week 12, three weeks after the forth cycle of TC chemotherapy had been administered.
Serum estradiol levels were determined at BML Inc. (Tokyo, Japan) using a direct immunoassay performed on the Architect-i2000 (Abbott Laboratories, North Chicago, IL), which has an analytic sensitivity of 10 pg/ml, according to the manufacturer’s protocol, with an extended standard curve to allow for a lower limit of detection of 5 pg/ml.
The sample size was too small to use an unpaired statistical test; therefore, Spearman’s rank correlation coefficient (ρ) was calculated using repeated measurements of serum FSH levels in 29 women. From the ρ value, t was obtained.
Serum estradiol levels decreased to below 18.7 pg/ml (median 5.5 pg/ml, range <5–18.7 pg/ml, n = 15) and FSH levels increased to a median of 63.9 mIU/ml (24.5–127.4 mIU/ml) as early as week 6, after two cycles of chemotherapy. At week 9, serum estradiol levels decreased to a median of 6.6 pg/ml (range <5–16.9 pg/ml, n = 29) and serum FSH levels increased to a median of 66.8 mIU/ml (range 33.9–134.5 mIU/ml). Furthermore, at week 12, 3 weeks after administration of the forth cycle of TC chemotherapy, estradiol levels remained decreased with a median value of 6.6 pg/ml (range <5–17.3 pg/ml, n = 20) and FSH levels were still increased with a median value of 66.1 mIU/ml (range 29.2–101 mIU/ml).
At the 2-year assessment, five women (ages 32–48, median 39) resumed menses, confirmed by laboratory measurements, among 20 patients who received tamoxifen only without LHRH analog treatment (ages 32–52, median 45) after chemotherapy completion, with the fastest occurring at week 21. Discordance between laboratory data and patient-recorded vaginal bleeding was observed in two patients who had menstrual bleeding at week 7 among 15 patients whose laboratory data showed severe ovarian dysfunction at week 6.
This study included a small cohort of 35 patients; however, our findings that ovarian suppression at the time of chemotherapy completion was induced in patients treated with docetaxel, were consistent with and corroborated by previous observations in which docetaxel resulted in higher rates of transient CIA when used as adjuvant chemotherapy for premenopausal women with breast cancer (Berliere et al. 2008; Han et al. 2009).
It has been reported that cytotoxic agents, especially anthracyclines and alkylating agents such as cyclophosphamide, induce amenorrhea, potentially by activating apoptotic oocyte death in primordial follicles, which damages the ovarian reserve (Oktem & Oktay 2007). However, younger patients were found to be resistant to CIA because they have a larger primordial follicle pool (Oktem & Oktay 2007). In studies of ovarian function after chemotherapy without docetaxel, the decrease in serum estradiol concentrations and increase in FSH levels showed greater variations than our observations (Yoo et al. 2013; Yu et al. 2010).
Mechanisms of gonadal toxicity caused by chemotherapeutic agents are complex. Colleoni et al. reported that three cycles of dose-intensive epirubicin and cyclophosphamide with filgrastim and progenitor cell support significantly improved DFS only in patients with ER-positive disease, and resulted in higher rates of CIA even in patients <40 years old. Their CIA criterion for premenopausal patients was no menses during months 7–9 from randomization (Colleoni et al. 2009). Amenorrhea induced by modern-day chemotherapies appears to be characterized by rapid occurrence and is age-non-specific and transient, contrary to the features of first generation chemotherapy, such as CMF-induced amenorrhea, which occurs at an increasing rate with the passage of time, shows resistance in younger-aged patients, and is permanent.
Docetaxel, given after anthracycline-containing regimens, induced muscle and joint pain in 53–87% of patients (Saibil et al. 2010; Eckhoff et al. 2011). Taxanes (paclitaxel and docetaxel) can induce arthralgia and myalgia in up to 75% of patients (Nugalieva et al. 2010). There are several differences in the toxicity profiles of docetaxel and paclitaxel. Paclitaxel can induce disabling but transient arthralgia and myalgia, called acute pain syndrome, which has been hypothesized to be caused by neurologic injury (Wolf et al. 2008). The incidence of docetaxel-induced peripheral neuropathy is much lower than that of paclitaxel-induced peripheral neuropathy and is usually mild, disappearing spontaneously after discontinuation of therapy (Quasthoff & Hartung 2009; Balayssac et al. 2011).
Symptoms caused by a rapid decline in estrogen levels induced by docetaxel treatment might be overlooked because of the diversity of symptoms and the complexity associated with neuromuscular assessment. There are a few reports that have explored the relationship between pain and rapid decline in estrogens such as that caused by surgical menopause (Fang et al. 2009), but low estrogen levels can lead to an increase in aches and pains. Many women first report joint pain when they are perimenopausal or approaching menopause, though whether aches and joint pains are associated with hormonal changes due to menopausal transition is controversial. The data presented in this study provide a novel aspect of transient CIA by measuring serum estradiol and FSH levels during and after completion of docetaxel-containing chemotherapy, which can be used to track the impact of adherence to treatment, especially for younger patients whose biological changes are more variable than those in patients who are approaching menopause.
Despite the limitations of our study, which was a small single-center pilot study, our findings demonstrated that docetaxel induced a brief period of amenorrhea close to the last cycle of chemotherapy in premenopausal ER-positive breast cancer patients. To understand the hormonal environment and its relationship with a patient’s state as well as symptoms caused by docetaxel-containing chemotherapy, more time points to monitor ovarian function and more patients are needed. Further study is warranted.
We thanks BML Inc. for technical supports to allow for a lower detection limit of ordinary analytic sensitivity of serum estradiol.
- Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA: The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006, 21: 2583-2592.View ArticleGoogle Scholar
- Balayssac D, Ferrier J, Descoeur J, Ling B, Pezet D, Eschalier A, Authier N: Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf 2011, 10: 407-417. doi:10.1517/14740338.2011.543417View ArticleGoogle Scholar
- Berliere M, Dalenc F, Malingret N, Vindevogel A, Piette P, Roche H, Donnez J, Symann M, Kerger J, Machiels JP: Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer 2008, 8: 56. doi:10.1186/1471-2407-8-56View ArticleGoogle Scholar
- Colleoni M, Sun Z, Martinelli G, Basser RL, Coates AS, Gelber RD, Green MD, Peccatori F, Cinieri S, Aebi S, Viale G, Price KN, Goldhirsch A, International Breast Cancer Study Group: The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol 2009, 20: 1344-1951. doi:10.1093/annonc/mdp024View ArticleGoogle Scholar
- Eckhoff L, Nielsen M, Moeller S, Knoop A: TAXTOX- a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Acta Oncol 2011, 50: 1075-1082. doi:10.3109/0284186X.2011.602111View ArticleGoogle Scholar
- Fang CY, Cherry C, Devarajan K, Li T, Malick J, Daly MB: A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol Oncol 2009, 112: 594-600. doi:10.1016/j.ygyno.2008.11.039View ArticleGoogle Scholar
- Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ, 10th St. Gallen conference: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18: 1133-1144. doi:10.1093/annonc/mdm271View ArticleGoogle Scholar
- Han HS, Ro J, Lee KS, Nam BH, Seo JA, Lee DH, Lee H, Lee ES, Kang HS, Kim SW: Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Tr 2009, 115: 335-342.View ArticleGoogle Scholar
- Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006, 24: 5381-5387.View ArticleGoogle Scholar
- Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009, 27: 1177-1183.View ArticleGoogle Scholar
- Knobf MT: The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist 2006, 11: 96-110.View ArticleGoogle Scholar
- Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008, 26: 2373-2378. doi:10.1200/JCO.2007.144287View ArticleGoogle Scholar
- Nugalieva Z, Xia R, Liu CC, Burau K, Hardy D, Du XL: Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer. Am J Ther 2010, 17: 148-158. doi:10.1097/MJT.0b013e3181a3e50bView ArticleGoogle Scholar
- Oktem O, Oktay K: A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res 2007, 67: 10159-10162.View ArticleGoogle Scholar
- Park IH, Han HS, Lee H, Lee KS, Kang HS, Lee S, Kim SW, Jung S, Ro J: Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer. Ann Oncol 2012, 23: 2283-2289. doi:10.1093/annonc/mds006View ArticleGoogle Scholar
- Parulekar WR, Day AG, Ottaway JA, Shepherd LE, Trudeau ME, Bramwell V, Levine M, Pritchard KI National Cancer Institute of Canada Clinical Trials Group: Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study—NCIC CTG MA.5. J Clin Oncol 2005, 23: 6002-6008.View ArticleGoogle Scholar
- Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol 2009, 249: 9-17.View ArticleGoogle Scholar
- Saibil S, Fitzgerald B, Freedman OC, Amir E, Napolskikh J, Salvo N, Dranitsaris G, Clemons M: Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr Oncol 2010, 17: 42-47.View ArticleGoogle Scholar
- Swain SM, Land SR: Amenorrhea in premenopausal women on the doxorubicin- and-cyclophosphamide-followed-by docetaxel arm of NSABP B-30 trial. Breast Cancer Res Tr 2009, 113: 315-320.View ArticleGoogle Scholar
- Swain SM, Jeong JH, Wolmark N: Amenorrhea from breast cancer therapy–not a matter of dose. N Engl J Med 2010, 363: 2268-2270.View ArticleGoogle Scholar
- Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N: Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010, 362: 2053-2065. doi:10.1056/NEJMoa09096389View ArticleGoogle Scholar
- Wolf S, Barton O, Kottschade L, Grothey A, Loprinzi C: Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008, 44: 1507-1515. doi: 10.1016/j.ejca.2008.04.018View ArticleGoogle Scholar
- Yoo C, Yun MR, Ahn JH, Jung KH, Kim HJ, Kim JE, Park JY, Park KO, Yoon DH, Kim SB: Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study. Cancer Chemother Pharmacol 2013, 72: 565-575. doi:10.1007/s00280-013-2227-5View ArticleGoogle Scholar
- Yu B, Doglas N, Ferin MJ, Nakhuda GS, Crew K, Lobo RA, Hershman DL: Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 2010, 116: 2099-2105. doi:10.1002/cncr.25037Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.